Acute leukemia in a patient cured of diffuse histiocytic lymphoma

1986 ◽  
Vol 112 (1) ◽  
pp. 67-70 ◽  
Author(s):  
Janice P. Dutcher ◽  
Peter H. Wiernik
Keyword(s):  
Acute Leukemia ◽  
Histiocytic Lymphoma ◽  
Diffuse Histiocytic Lymphoma

Richter's syndrome: Diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia

1980 ◽  
Vol 68 (4) ◽  
pp. 539-548 ◽  
Author(s):  
Donald L. Trump ◽  
Risa B. Mann ◽  
Roger Phelps ◽  
Huw Roberts ◽  
C.Lockard Conley
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Histiocytic Lymphoma ◽  
Diffuse Histiocytic Lymphoma ◽  
Richter’S Syndrome

Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma

1979 ◽  
Vol 67 (6) ◽  
pp. 929-934 ◽  
Author(s):  
James O. Armitage ◽  
Fred R. Dick ◽  
Charles E. Platz ◽  
Michael P. Corder ◽  
Joseph T. Leimert
Keyword(s):  
Clinical Usefulness ◽  
Histiocytic Lymphoma ◽  
Diffuse Histiocytic Lymphoma

Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen.

1984 ◽  
Vol 2 (8) ◽  
pp. 898-902 ◽  
Author(s):  
J O Armitage ◽  
M A Fyfe ◽  
J Lewis
Keyword(s):  
Colon Cancer ◽  
Sexual Dysfunction ◽  
Complete Remission ◽  
High Frequency ◽  
Chop Regimen ◽  
Histiocytic Lymphoma ◽  
Age Range ◽  
Diffuse Histiocytic Lymphoma ◽  
Disease Free

Thirty-eight (51%) of 75 patients treated with CHOP for diffuse histiocytic lymphoma achieved complete remission. Twenty-three of the complete responders are currently alive in complete remission 24-78 months (median, 38 months) after discontinuing therapy. Eleven patients died from recurrent lymphoma and four patients died in complete remission from other causes. Evaluation of the 23 patients alive in complete remission found them mostly well and without serious sequelae to therapy. Comparison with 20 patients who were in the same age range, were disease free after surgery, and had no other therapy for colon cancer revealed only an increased frequency of sexual dysfunction in the chemotherapy-treated lymphoma patients. Sixty-one percent of patients who achieved complete remission with the CHOP regimen are long-term disease-free survivors and are generally well except for an apparently high frequency of sexual dysfunction.

scholarly journals Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma

Blood ◽  
1977 ◽  
Vol 49 (3) ◽  
pp. 325-333 ◽  
Author(s):  
V Rodriguez ◽  
F Cabanillas ◽  
MA Burgess ◽  
EM McKelvey ◽  
M Valdivieso ◽  
...  
Keyword(s):  
Malignant Lymphoma ◽  
Median Duration ◽  
Combination Chemotherapy ◽  
Stage Iv ◽  
Complete Response ◽  
Histiocytic Lymphoma ◽  
Duration Of Response ◽  
Severe Infections ◽  
Poorly Differentiated ◽  
Diffuse Histiocytic Lymphoma

Abstract Forty-seven adults with advanced malignant lymphoma (the majority in stage IV) were treated with a combination of cyclophosphamide, hydroxyldaunorubicin (Adriamycin), vincristine (Oncovin), prednisone, and bleomycin (CHOP-Bleo). The complete remission (CR) rate was 66%. The overall response (complete + partial remission) was 92%. The CR rate in patients with diffuse histiocytic lymphoma (DHL) was 69%. Only 3 of the 18 patients with DHL in CR have relapsed; the projected median duration of response was calculated to be greater than 2 yr. In patients with nodular poorly differentiated lymphocytic lymphoma (NPDL), the CR rate was 62%. One of the eight patients with NPDL in CR has relapsed; the projected median duration of complete response will be greater than 4 yr. The median survival for all patients entered in this study has not been reached; however, it was estimated that it will be greater than 3 yr. The survival curves became flat at 70 wk for the patients with DHL and at 1 yr for the patients with NPDL. Major complications during chemotherapy with CHOP-Bleo were myelosuppression and alopecia. Only six severe infections occurred during myelosuppression. No hemorrhagic problems were observed. This study indicates that combination chemotherapy with these agents is effective in increasing the CR rate and survival in patients with diffuse histiocytic lymphoma. In patients with NPDL, further observation will be needed to assess the effect of this combination on survival.

DIFFUSE HISTIOCYTIC LYMPHOMA: THE 20-YEAR EXPERIENCE OF AN AUSTRALIAN TEACHING HOSPITAL

1988 ◽  
Vol 18 (6) ◽  
pp. 758-763
Author(s):  
J. N. C. BURROW ◽  
J. WRIGHT ◽  
C. A. JUTTNER ◽  
K. S. CROWLEY ◽  
R. J. KIMBER
Keyword(s):  
Teaching Hospital ◽  
Histiocytic Lymphoma ◽  
Diffuse Histiocytic Lymphoma ◽  
Australian Teaching Hospital

scholarly journals The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis

Blood ◽  
1979 ◽  
Vol 54 (6) ◽  
pp. 1428-1433
Author(s):  
DJ Straus ◽  
M Andreeff ◽  
HJ Hansen ◽  
R Mertelsmann ◽  
B Koziner ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Flow Cytometry ◽  
Lymph Node ◽  
Dna Content ◽  
Acute Myeloblastic Leukemia ◽  
Histiocytic Lymphoma ◽  
Cellular Dna ◽  
Multiparameter Analysis ◽  
Diploid Cells ◽  
Diffuse Histiocytic Lymphoma

Measurement of cellular DNA content by flow cytometry demonstrated presence of two distinct aneuploid neoplasms in a patient who developed acute myeloblastic leukemia (AML) 4 mo after diagnosis of a diffuse histiocytic lymphoma (DHL). A lymph node aspirate contained peroxidase- negative, “null,” hyperdiploid (2.6C) DHL cells, while the bone marrow (BM) contained 84% primitive peroxidase-positive tetraploid AML cells (4.0C). Minor populations of hyperdiploid HDL and normal diploid cells could be detected by flow-cytometry in the BM, and all three populations were also seen in the peripheral blood.

Sign in / Sign up

Export Citation Format

Share Document